FcRH5xCD3 bispecific antibody cevostamab in relapsed or refractory multiple myeloma: a phase 1 trial. (nature.com)

Authors: Cohen AD … Krishnan A Journal: Nature Medicine Published: 2026-07-22 DOI: https://doi.org/10.1038/s41591-026-04522-3